Genetic polymorphism of rare mutations in Mycobacterium tuberculosis-infected patients in Delhi by Himanshu Vashistha, Mahmud Hanif, Kamal Kishore Chopra, Divya Shrivastava, Ashwani Khanna

Subjects: Get full text

An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mut... by Keunchil Park, Jin-Soo Kim, Joo-Hang Kim, Young-Chul Kim, Hoon-Gu Kim, Eun Kyung Cho, Jong-Youl Jin, Miyoung Kim, Angela Märten, Jin-Hyoung Kang

Subjects: Get full text

Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study by Yung-Hsuan Chen, Yen-Fu Chen, Chung-Yu Chen, Jin-Yuan Shih, Chong-Jen Yu

Subjects: Get full text

Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review by Yingying Jiang, Xiaoxu Fang, Yan Xiang, Tingwen Fang, Jingwen Liu, Kaihua Lu

Subjects: Get full text

Correlation of TTF-1 immunoexpression and EGFR mutation spectrum in non–small cell lung carcinoma by Tripti Nakra, Varsha Singh, Aruna Nambirajan, Prabhat Singh Malik, Anant Mohan, Deepali Jain

Subjects: Get full text

A rare epidermal growth factor receptor H773L/V774M compound mutation in advanced non‐small‐cell lung cancer with poor response to epidermal growth factor receptor tyrosine kinase... by Lun‐Che Chen, Jin‐Yuan Shih, Chong‐Jen Yu, Ching‐Yao Yang

Subjects: Get full text

Epidermal growth factor receptor tyrosine kinase inhibitors for non‐small cell lung cancer harboring uncommon EGFR mutations: Real‐world data from Taiwan by John Wen‐Cheng Chang, Chen‐Yang Huang, Yueh‐Fu Fang, Ching‐Fu Chang, Cheng‐Ta Yang, Chih‐Hsi Scott Kuo, Ping‐Chih Hsu, Chiao‐En Wu

Subjects: Get full text

Budget Impact Analysis of afatinib for first-line treatment of Non-Small Cell Lung Cancer (NSCLC) patients with uncommon EGFR mutations by Giuseppe Pompilio, Alessandro Morabito, Diego L. Cortinovis, Davide Integlia

Subjects: Get full text

Effectiveness of Tyrosine Kinase Inhibitors on Uncommon Epidermal Growth Factor 
Receptor Mutations in Non-small Cell Lung Cancer by Xue YANG, Hanxiao CHEN, Hong ZHANG, Jianchun DUAN, Tongtong AN, Jun ZHAO, Minglei ZHUO, Meina WU, Jie WANG

Subjects: Get full text

Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations by Teng Li, Shouzheng Wang, Jianming Ying, Yan Wang, Xingsheng Hu, Xuezhi Hao, Ziyi Xu, Puyuan Xing, Junling Li

Subjects: Get full text

Effectiveness of EGFR tyrosine kinase inhibitors in advanced non‐small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study by Masaki Kanazu, Masahide Mori, Madoka Kimura, Kazumi Nishino, Takayuki Shiroyama, Izumi Nagatomo, Shoichi Ihara, Kiyoshi Komuta, Hidekazu Suzuki, Tomonori Hirashima, Toru Kumagai, Fumio Imamura

Subjects: Get full text

Chemotherapy outcomes in EGFR‐TKI resistant patients with common and uncommon EGFR mutation: An exploratory retrospective cohort study by Chien‐Yu Lin, Chia‐Hao Hu, Chia‐Fu Hsu, Jeng‐Shiuan Tsai, Chian‐Wei Chen, Chia‐Yin Lin, Chao‐Chun Chang, Yi‐Ting Yen, Yau‐Lin Tseng, Po‐Lan Su, Chien‐Chung Lin

Subjects: Get full text

A Review of EGFR-TKIs Therapy of Non-small Cell Lung Cancer
with Uncommon EGFR Mutations by Wenxing DU, Yang WO, Tong LU, Yuanyong WANG, Wenjie JIAO

Subjects: Get full text

Successful sequential tyrosine kinase inhibitors to overcome a rare compound of EGFR exon 18–18 and EGFR amplification: A case report by Pascal Wang, Emmanuelle Fabre, Emmanuelle Fabre, Antoine Martin, Kader Chouahnia, Ambre Benabadji, Lise Matton, Boris Duchemann, Boris Duchemann

Subjects: Get full text

“Sandwich” Strategy to Intensify EGFR Blockade by Concurrent Tyrosine Kinase Inhibitor and Monoclonal Antibody Treatment in Highly Selected Patients by Guoqing Zhang, Beibei Yan, Yanan Guo, Hang Yang, Jindong Li

Subjects: Get full text

Survival analysis of patients with advanced non-small cell lung cancer receiving EGFR-TKI treatment of Yunnan in southwestern China: a real-world study by Yanping Lin, Long Chen, Rong Li, Xin Liu, Quan Li, Jingjing Cai, Yaxi Du, Guangqiang Zhao, Xiaoxiong Wang, Zhenghai Shen, Yedan Liao, Yang Chen, Lin Xie, Yongchun Zhou, Yunchao Huang

Subjects: Get full text

Successful Treatment of Afatinib-Refractory Non-Small Cell Lung Cancer with Uncommon Complex EGFR Mutations Using Pembrolizumab: A Case Report by Yuri Taniguchi, Momoko Yamamoto, Hiroaki Ikushima, Sayaka Ohara, Hideyuki Takeshima, Toshio Sakatani, Kazuhiro Usui

Subjects: Get full text

Activity of afatinib in patients with NSCLC harboring novel uncommon EGFR mutations with or without co-mutations: a case report by Petros Christopoulos, Petros Christopoulos, Franziska Herster, Petra Hoffknecht, Markus Falk, Markus Falk, Markus Tiemann, Markus Tiemann, Hans-Georg Kopp, Andre Althoff, Anja Stammberger, Eckart Laack

Subjects: Get full text

EGFR Exon 18 Mutations in Advanced Non-Small Cell Lung Cancer: A Real-World Study on Diverse Treatment Patterns and Clinical Outcomes by Haiyan Xu, Guangjian Yang, Weihua Li, Junling Li, Xuezhi Hao, Puyuan Xing, Yaning Yang, Yan Wang

Subjects: Get full text

Editorial: Challenges and opportunities of TKIs in the treatment of NSCLC patients with uncommon mutations by Chunxia Su, Shi-Yong Sun

Subjects: Get full text